Company profile for Nuravax

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Nuravax is developing next-generation preventive vaccines for Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders. Our research focuses on creating safe, effective vaccines that target the underlying causes of these conditions before symptoms appear. Using our proprietary vaccine platform, we stimulate protective immune responses against harmful proteins like amyloid beta and tau, which are associ...
Nuravax is developing next-generation preventive vaccines for Alzheimer's disease, Parkinson's disease, and related neurodegenerative disorders. Our research focuses on creating safe, effective vaccines that target the underlying causes of these conditions before symptoms appear. Using our proprietary vaccine platform, we stimulate protective immune responses against harmful proteins like amyloid beta and tau, which are associated with disease progression. These vaccines are designed to produce antibodies that can cross the blood-brain barrier to neutralize toxic protein aggregates where they form.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
5270 California Ave., Suite 300 Irvine, CA 92617
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Tides Asia

Tides Asia

Not Confirmed

envelop Contact Supplier

Tides Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/nuravax-institute-for-molecular-medicine-to-present-phase-1-results-and-phase-2-design-of-alzheimers-vaccine-av-1959r-at-ctad-2025-302495153.html

PR NEWSWIRE
01 Jul 2025

https://www.prnewswire.com/news-releases/breakthrough-alzheimers-vaccine-duvax-secures-3-million-nih-grant-to-launch-us-clinical-trials-302446078.html

PR NEWSWIRE
05 May 2025

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty